Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:1148 (24 May), doi:10.1136/bmj.39583.774769.3A
| The first 100% of the full text of this article appears below. |
I strongly disagree with Lewarss conclusion about the use of hormone replacement therapy (HRT) in women with a premature menopause.1 He is quoting the Womens Health Initiative, which was undertaken in women older than 50 and does not pertain to women in their 30s or even younger with early ovarian failure.
Women with untreated premature menopause are at increased risk of developing osteoporosis, cardiovascular disease, cognitive decline, dementia, and parkinsonism.2 3 Therefore, a need for oestrogen replacement exists until the average age of the natural menopause, which is about 52 in the United Kingdom. This does not increase the risk of breast cancer.4 The recommendation for HRT use by Jones et al is in accordance with national guidelines.5
Margaret C P Rees, reader in reproductive medicine, University of Oxford
1 Womens Centre, John Radcliffe Hospital, Oxford OX3 9DU
margaret.rees@obs-gyn.ox.ac.uk
Israeli students are refusing to perform intimate examinations on anaesthetised women without their informed consent.